Clinical Trials

argenx has clinical trials ongoing across its differentiated antibody pipeline

Efgartigimod

Myasthenia Gravis (MG)

ADAPT

Phase 3 trial of IV efgartigimod for the treatment of generalized MG. Completed.
Program: Efgartigimod

More information

Primary Immune Thrombocytopenia (ITP)

ADVANCE

Phase 3 trial of IV efgartigimod for the treatment of primary ITP
Program: Efgartigimod

More information

argenx ITP Study website

ADVANCE SC

Phase 3 trial evaluating SC efgartigimod for the treatment of primary ITP
Program: Efgartigimod

More information
argenx ITP SC Study website

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

ADHERE

Phase 2 trial of SC Efgartigimod for the treatment of CIDP
Program: Efgartigimod

More information
argenx CIDP Study website

Pemphigus Vulgaris (PV)

ADDRESS

Phase 3 trial of IV efgartigimod for the treatment of PV.
Program: Efgartigimod

More information
argenx PV Study website

Cusatuzumab

Acute Myeloid Leukemia (AML)

CULMINATE

A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia who are not Candidates for Intensive Chemotherapy
Program: Cusatuzumab

More information

Cusatuzumab Combination (AML)

Cusatuzumab in Combination with Background Therapy for the Treatment of Participants with Acute Myeloid Leukemia
Program: Cusatuzumab

More information

Cusatuzumab with Japanese Participants

A Study of Cusatuzumab Plus Azacitidine in Japanese Participants with Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome who are not Candidates for Intensive Treatment
Program: Cusatuzumab

ARGX-117

Severe Autoimmunity

ARGX-117

ARGX-117 Phase 1 healthy volunteer trial
Program: ARGX-117